Long-Term Infectious and Noninfectious Outcomes of Monthly Alemtuzumab as a Calcineurin Inhibitor- and Steroid-Free Regimen for Pancreas Transplant Recipients

<div>Cumulative incidence of cellular mediated rejection. EAE: extended alemtuzumab exposure; SIM: standard induction and maintenance therapy.</div>

Canadian Journal of Infectious Diseases and Medical Microbiology

fig2

Figure 2

Figure 2: Long-Term Infectious and Noninfectious Outcomes of Monthly Alemtuzumab as a Calcineurin Inhibitor- and Steroid-Free Regimen for Pancreas Transplant Recipients 

Figure 2 | Long-Term Infectious and Noninfectious Outcomes of Monthly Alemtuzumab as a Calcineurin Inhibitor- and Steroid-Free Regimen for Pancreas Transplant Recipients 